Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY)

Tipranks - Tipranks - Tue Apr 7, 6:58AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY).

Easter Sale - 70% Off TipRanks

UnitedHealth (UNH)

Goldman Sachs analyst Scott Fidel maintained a Buy rating on UnitedHealth on April 2 and set a price target of $400.00. The company’s shares closed last Thursday at $277.26.

According to TipRanks.com, Fidel is a 5-star analyst with an average return of 8.9% and a 63.6% success rate. Fidel covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and Oscar Health. ;'>

Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $368.15, representing a 35.2% upside. In a report issued on April 1, Raymond James also upgraded the stock to Buy with a $330.00 price target.

See today’s best-performing stocks on TipRanks >>

IDEAYA Biosciences (IDYA)

In a report released yesterday, Maury Raycroft from Jefferies maintained a Buy rating on IDEAYA Biosciences, with a price target of $52.00. The company’s shares closed last Thursday at $32.74.

According to TipRanks.com, Raycroft is a 4-star analyst with an average return of 10.4% and a 42.1% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Dianthus Therapeutics, and Kezar Life Sciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IDEAYA Biosciences with a $54.80 average price target, a 71.1% upside from current levels. In a report issued on March 22, LifeSci Capital also maintained a Buy rating on the stock with a $62.00 price target.

Bristol-Myers Squibb (BMY)

In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00. The company’s shares closed last Thursday at $59.60, close to its 52-week high of $63.33.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.5% and a 47.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Teva Pharmaceutical, and Johnson & Johnson. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $62.94 average price target, which is a 4.5% upside from current levels. In a report issued on March 30, Bernstein also maintained a Hold rating on the stock with a $58.00 price target.

Read More on UNH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).